An organoids biobank for recapitulating tumor heterogeneity and personalized medicine

摘要

Recently, an original article titled “A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity” was published in Cell ( ), a leading journal of scientific research worldwide. This paper reported that Fadi Jacob and colleagues established an organoids biobank with patient-derived glioblastoma organoids (GBOs), recapitulating the histological features, cellular diversity, gene expression and mutational profiles of their corresponding parental tumors. And functions of these organoids were confirmed both and xenograft models. In addition, by modeling targeted drug testing and chimeric antigen receptor T cell (CAR-T) immunotherapy, they demonstrated the application of GBOs in personalized medicine ( ) ( ). These discoveries provided an effective platform for basic and translational cancer research characterized by high degree of heterogeneity and contributed to the investigation of personalized medicine. Here in this commentary, we provide a concise explanation of this biobank and its impacts on clinical cancer therapy.